DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,911,211 B2 Eini Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,911,211 B2 Eini Et Al USOO6911211B2 (12) United States Patent (10) Patent No.: US 6,911,211 B2 Eini et al. (45) Date of Patent: Jun. 28, 2005 (54) PHARMACEUTICAL AND COSMETIC Jun. 27, 2000 (IL) ................................................ 137051 CARRIER OR COMPOSITION FOR Jun. 27, 2000 (IL) ................................................ 137052 TOPCAL APPLICATION (51) Int. Cl." ............................ A61K 7/00; A61K 7/48; (75) Inventors: Meir Eini, Nes Zions (IL); Dov A61K 31/74 Tamarkin, Maccabim (IL) (52) U.S. Cl. ................. 424/401; 424/78.03; 424/78.06; (73) Assignee: Foamix Ltd., Ness Ziona (IL) 424/445 (*) Notice: Subject to any disclaimer, the term of this (58) Field of Search .............................. 424/401, 78.03, patent is extended or adjusted under 35 424/445, 78.06, 484; 514/181, 782 U.S.C. 154(b) by 0 days. (56) References Cited (21) Appl. No.: 10/169,897 (22) PCT Filed: Jan. 10, 2001 U.S. PATENT DOCUMENTS 5,719,197 A 2/1998 Kanios et al. (86) PCT No.: PCT/IL01/00025 5,837.270 A 11/1998 Burgess S371 (c)(1), 5,925,669 A 7/1999 Katz et al. (2), (4) Date: Dec. 31, 2002 Primary Examiner-Gary Kunz (87) PCT Pub. No.: WO01/51014 Assistant Examiner Mina Haghighatian (74) Attorney, Agent, or Firm Wilmer Cutler Pickering PCT Pub. Date:Jul.19, 2001 Hale and Dorr LLP (65) Prior Publication Data US 2004/0253275 A1 Dec. 16, 2004 (57) ABSTRACT A pharmaceutical or cosmetic carrier or composition for Related U.S. Application Data topical application characterized by rheological properties (63) Continuation-in-part of application No. 09/653,267, filed on which render the carrier or composition Semi-Solid at rest Aug. 31, 2000, which is a continuation-in-part of application and a liquid upon application of shear forces thereto. The No. 09/526,509, filed on Mar. 16, 2000, now Pat. No. composition or carrier are prepared by mixing 1-25 percent 6,348.229. (60) Provisional application No. 60/216,162, filed on Jul. 3, of a solidifying agent and 75-99 percent of a hydrophobic 2000. Solvent, by weight, wherein at least one of them has thera peutic or cosmetic benefits, in the presence or absence of a (30) Foreign Application Priority Data biologically active Substance. Jan. 10, 2000 (IL) ................................................ 133968 Jan. 10, 2000 (IL) ................................................ 133969 42 Claims, 1 Drawing Sheet U.S. Patent Jun. 28, 2005 US 6,911,211 B2 US 6,911,211 B2 1 2 PHARMACEUTICAL AND COSMETIC Skin diseases or disorders are usually treated by creams, CARRIER OR COMPOSITION FOR gels or ointments containing antifungal agents, Steroidal TOPCAL APPLICATION agents and/or antibacterial agents. In many instances Such creams, gels and ointments are difficult to Spread, result in This application is a 371 of PCT/IL01/00025 filed Jan. 5 a greasy and Sticky appearance and are usually not appealing 01, 2001, which is a continuation-in-part (CIP) of applica for use. tion Ser. No. 09/526,509 filed Mar. 16, 2000, now U.S. Pat. Genital infections are caused by fungal, Viral and micro No. 6,348,229, and a continuation-in-part (CIP) of applica bial agents. Genitals infections are treated either tion Ser. No. 09/653,267 filed Aug. 31, 2000, which claims Systematically, or by the use of creams, ointments or benefit of provisional Application No. 60/216,162 filed Jul. pessaries, which usually leak or otherwise fail to spread well 03, 2000. and lead to ineffective therapeutic concentration of the therapeutically active agent(s) therein. FIELD AND BACKGROUND OF THE Genital herpes infections are widespread from the 70's INVENTION and apart from the discomfort they inflict, genital herpes The present invention relates to a pharmaceutical or 15 infections may, in Some cases, develop into Severe disease. cosmetic carrier or composition for topical application onto Presently, there is no effective medication for genital herpes. skin and/or mucosal membranes (e.g., the mucosa of the Trichomoniasis is an infection of the urogenital tract nose, mouth, eye, ear, vagina or rectum). More particularly, caused due to infection by the protozoan Trichomonas the present invention relates to (i) a cosmetic or pharma vaginalis. Trichomoniasis is associated with uncomfort itch ceutical carrier or composition characterized by theological ing and vaginal excretion in Women. properties which render the carrier or composition Semi Candidiasis is caused by Candida albicans and results in Solid at rest and liquid upon application of Shear forces (e.g., itching in the genital area and white discharge therefrom. spread forces) thereto; (ii) methods of preparing same; and Mucosal membrane inflammations can affect other organs (iii) methods of utilizing same for treating a variety of skin Such as for example, the eye. Conjuctivitis, caused by or mucosal membrane diseases or disorders. 25 different types of bacteria, Such as, but not limited to, Most of the skin or mucosal membrane diseases or StaphylococcuS aureus, StreptococcuS pneumoniae or Hae disorders are the result of inflammation caused by inflam mophilus influenzae, is generally treated with antibiotic matory agents, Such as, but not limited to, bacterial, fungal, ointments, e.g., bacitracin 500 U/g or gentamicin 0.3 percent Viral, parasitic, autoimmune, allergic, hormonal and/or ophthalmic ointment instilled into the affected eye. The malignant inflammatory agents. The most common skin compliance to these ointments is usually poor due to the diseases or disorders include eczema, psoriasis and Sticky feeling they exert dermatitis, including contact dermatitis, atopic dermatitis AS is evident from the above descriptions, one of the and Seborrheic dermatitis. important routes of administration of a drug for treating a Eczema and dermatitis result from inflammatory pro 35 skin or mucosal membrane is is by topical application of a ceSSes that involve the upper dermis and epidermis of the drug onto the Skin or mucosal membrane. This method is skin. When eczema develops, the keratinocytes in the epi useful for local treatment but it is also possible to apply dermis distend from one another and fluid is accumulated pessaries via the rectum as an efficient delivery method of there amongst in a process known as Spongiosis. Systemic agents that are not degraded in the intestine. In chronic forms of eczema or dermatitis the main change 40 Many pharmaceutical carriers are presently known, most include thickening of the epidermis, which leads to itching, of them have disadvantages when topically applied onto the roughening and Scaling of the skin Surface. The loss of water skin or mucosal membranes. For example, when ointments from the Skin leads to inflammation of the horny layer, containing petroleum as a carrier are applied onto a skin which later result in cracked and Sore skin. wound, metabolic products and excreta from the wound 45 cannot be casily removed therefrom because of the difficulty Dermatitis is further classified into contact dermatitis of passing through the hydrophobic petroleum barrier. In (allergic or non allergic), atopic dermatitis and Seborrheic addition, the active drug ingredient, which is dissolved or dermatitis. dispersed in the petroleum carrier, is not efficiently absorbed Non allergic contact dermatitis occurs in response to skin into the wound tissue, thus, the efficacy of the drug is irritants, Such as acids, alkalis, oils, detergents and Solvents. 50 affected. Another example is ophthalmologic ointments, Allergic contact dermatitis occurs as a result of Sensiti which are applied into the eye, and make the eye area Sticky Zation to repeated exposure to an antigen. Allergic contact and uncomfortable. Moreover, in physiological aspect, dermatitis appears in Skin areas that were in direct contact petroleum restricts respiration of a wound tissue and is with the antigen. disturbing to the normal respiration of the skin. Atopic dermatitis, which affects mainly infants, is char 55 Many groups of drugs including, for example, antibiotic, acterized by Sensitization of the skin to a wide range of antifungal, antiinflammatory, anesthetic, analgesic, common antigens. antiallergic, corticosteroid, retinoid and antiproliferative Seborrheic dermatitis affects the scalp and other hairy medications are preferably administered typically using a areas, the face, and flexural areas and results from yeast or hydrophobic carrier Such as petroleum. However, due to the bacteria induced inflammation. Most people suffer from 60 undesirable consistency of petroleum and Similar hydropho dandruff which is a mild form of Seborrheic dermatitis. bic carriers, their topical use is limited. An additional Psoriasis is a dominant autosomal inherited inflammatory disadvantage of petroleum-carrier including products relates disease characterized by enhanced proliferation of kerati to the greasy feeling following their topical application to nocytes which proliferation leads to formation of Scaly the skin or mucosal membranes. plaques on, for example, the knees, elbows, buttocks, and 65 Besides petroleum, other hydrophobic pharmaceutical which are esthetically unpleasant and cause discomfort to carriers are known, including liquid paraffin, lanolin, the affected subject. beeswax, vegetable oil, glycerin monoStearate, higher US 6,911,211 B2 3 4 alcohols, polyethylene glycol and Some emulsifying agents. disorder of a skin or a mucosal membrane, the method All of these agents either suffer the limitations described comprising the Step of topically administrating to the skin or hereinabove with respect to
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 31/57 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/14 (2006.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/56 (2006.01) A61K 31/58 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/040560 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 2 June 2014 (02.06.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/830,53 1 3 June 2013 (03.06.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: TOLMAR, INC.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0008537 A1 Wu Et Al
    US 20060008537A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0008537 A1 Wu et al. (43) Pub. Date: Jan. 12, 2006 (54) METHOD OF TREATING ACNE (22) Filed: Jul. 7, 2004 (76) Inventors: Jeffrey M. Wu, Warrington, PA (US); Publication Classification Jue-Chen Liu, Belle Mead, NJ (US); Jeannette Chantalat, Princeton, NJ (51) Int. Cl. (US); Ying Sun, Belle Mead, NJ (US) A61K 33/04 (2006.01) (52) U.S. Cl. .............................................................. 424/705 Correspondence Address: PHILIP S. JOHNSON JOHNSON & JOHNSON (57) ABSTRACT ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003 (US) The invention features a composition including an anti-acne agent, an antimicrobial agent, and a lactate, and the use (21) Appl. No.: 10/886,314 thereof in the treatment of acne. US 2006/0008537 A1 Jan. 12, 2006 METHOD OF TREATING ACNE made on the product containing the composition or in Stores, magazines, newspaper, radio, television, internet, and the BACKGROUND OF THE INVENTION like. 0001 Acne is a skin disorder that is often accompanied 0010. The compositions of the present invention are by pimples that Sometimes cause acne Sufferers embarrass useful for treating follicular diseases, Such as acne, Sebor ment. Consumers have utilized topical anti-acne agents, rhea, follicular rash, follicular infections Such as folliculitis Such as Salicylic acid and benzoyl peroxide to treat acne for and pSudofolliculitis barbe, follicular ketarosis, keratosis many years. Topical anti-acne agents typically function by pilaris, phrynoderma, ichthyosis follicularis, alopecia, folli exfoliating skin and/or killing bacteria on the Surface of the cular dysplasia, hirsutism, and hypertrichosis. AS used skin.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Wo 2009/063493 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 22 May 2009 (22.05.2009) PCT WO 2009/063493 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/58 (2006.01) A61K 31/575 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, PCT/IN2008/000577 EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (22) International Filing Date: LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, 8 September 2008 (08.09.2008) MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, (25) Filing Language: English RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1725/MUM/2007 kind of regional protection available): ARIPO (BW, GH, 10 September 2007 (10.09.2007) IN GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): GLEN- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), MARK PHARMACEUTICALS LIMITED [IN/IN]; European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, Glenmark house, HDO-Corporate Bldg, Wing-A, B.D FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, Sawant Marg, Chakala, Andheri (East), Maharashtra (IN).
    [Show full text]
  • Method and Composition for Testosterone Transdermal
    (19) TZZ_Z¥_T (11) EP 1 896 038 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61P 15/00 (2006.01) A61K 31/568 (2006.01) 09.11.2016 Bulletin 2016/45 A61K 31/57 (2006.01) A61K 8/63 (2006.01) A61K 9/08 (2006.01) A61Q 15/00 (2006.01) (21) Application number: 06741180.1 (86) International application number: (22) Date of filing: 02.06.2006 PCT/AU2006/000763 (87) International publication number: WO 2006/128255 (07.12.2006 Gazette 2006/49) (54) METHOD AND COMPOSITION FOR TESTOSTERONE TRANSDERMAL DELIVERY VERFAHREN UND ZUSAMMENSETZUNG FÜR DIE TRANSDERMALE ABGABE VON TESTOSTERON METHODE ET COMPOSITION POUR L’ADMINISTRATION TRANSDERMIQUE DE LA TESTOSTERONE (84) Designated Contracting States: • WILKINS, Nina AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Kensington, Victoria 3031 (AU) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Schnappauf, Georg et al ZSP Patentanwälte PartG mbB (30) Priority: 03.06.2005 AU 2005902902 Radlkoferstrasse 2 23.12.2005 US 752884 P 81373 München (DE) (43) Date of publication of application: (56) References cited: 12.03.2008 Bulletin 2008/11 WO-A1-2004/091631 WO-A1-2005/039531 WO-A1-2005/049026 WO-A2-2004/080413 (73) Proprietor: Acrux DDS Pty Ltd GB-A- 1 192 003 US-A- 5 962 505 West Melbourne, US-A1- 2001 051 157 US-A1- 2004 028 725 Victoria 3003 (AU) US-A1- 2004 175 416 US-A1- 2005 020 552 US-A1- 2005 025 833 US-A1- 2005 042 268 (72) Inventors: US-A1- 2005 049 233 • DI PIETRO, Tony Templestowe Lower, Victoria 3107 (AU) • BEN-GALIM E ET AL: "TOPICALLY APPLIED • HUMBERSTONE, Andrew TESTOSTERONE AND PHALLIC GROWTH ITS Elsternwick, Victoria 3185 (AU) EFFECT IN MALE CHILDREN WITH • GONDA, Igor HYPOPITUITARISM AND MICROPHALLUS", South Yarra, Victoria 3141 (AU) AMERICAN JOURNAL OF DISEASES OF • WATKINSON, Adam CHILDREN, AMERICAN MEDICAL SOCIETY, US, Williamtown, Victoria 3016 (AU) vol.
    [Show full text]